Health Care

Siemens Healthineers leads the 12‑15% CAGR POC diagnostics boom, blending AI analytics, cloud data and modular hardware to drive volume growth while navigating margin and regulatory challenges.

AbbVie secures EU approval for a high‑response bispecific antibody in relapsed follicular lymphoma, boosting its oncology portfolio and investor appeal.

Discover why Sartorius AG’s 1H 2026 results show a modest earnings uptick driven by biopharma growth, R&D investment, and new global partnerships, positioning the company for future bioprocessing success.

Shares dipped after Bayer announced a €3bn Apollo financing of its LARC business, keeping control while boosting liquidity amid litigation and market uncertainty.

UnitedHealth’s earnings preview focuses on its AI‑driven health services—boosting cost savings, care quality, and revenue while meeting strict safety and regulatory standards.

Johnson & Johnson secures FDA approval for its dual‑energy RF/PF catheter, boosting vascular device revenue while navigating pricing, competition, and patent cliffs.

AstraZeneca’s share price plunged 10% after its Wainua cardiovascular trial failed, but analysts note a resilient pipeline and M&A plans that could offset the loss.

Discover how Bristol‑Myers Squibb’s deucravacitinib, a selective TYK2 inhibitor, offers a steroid‑sparing, oral solution for SLE with proven Phase III renal benefits.

Discover how Cigna’s July 2026 Form 3 filings reveal executive equity strategies, dilution risks, and ESG opportunities—insights every investor needs.

Labcorp’s new $0.35 quarterly dividend and expanded DPYD pharmacogenomic testing underline its dual focus on shareholder returns and precision medicine advancements, boosting patient safety and cost‑efficiency.